Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors.
Adolescent
Adult
Age Factors
Aged
Brain Neoplasms
/ epidemiology
Cancer Survivors
Female
Glioma
/ epidemiology
Humans
Incidence
Leukoencephalopathies
/ diagnostic imaging
Magnetic Resonance Imaging
Male
Middle Aged
Polymorphism, Single Nucleotide
Progression-Free Survival
Radiation Injuries
Radiotherapy
/ adverse effects
Retrospective Studies
Risk Factors
Smoking
Survivors
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 05 2021
13 05 2021
Historique:
received:
26
10
2020
accepted:
16
04
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
3
11
2021
Statut:
epublish
Résumé
The incidence and risk factors associated with radiation-induced leukoencephalopathy (RIL) in long-term survivors of high-grade glioma (HGG) are still poorly investigated. We performed a retrospective research in our institutional database for patients with supratentorial HGG treated with focal radiotherapy, having a progression-free overall survival > 30 months and available germline DNA. We reviewed MRI scans for signs of leukoencephalopathy on T2/FLAIR sequences, and medical records for information on cerebrovascular risk factors and neurological symptoms. We investigated a panel of candidate single nucleotide polymorphisms (SNPs) to assess genetic risk. Eighty-one HGG patients (18 grade IV and 63 grade III, 50M/31F) were included in the study. The median age at the time of radiotherapy was 48 years old (range 18-69). The median follow-up after the completion of radiotherapy was 79 months. A total of 44 patients (44/81, 54.3%) developed RIL during follow-up. Twenty-nine of the 44 patients developed consistent symptoms such as subcortical dementia (n = 28), gait disturbances (n = 12), and urinary incontinence (n = 9). The cumulative incidence of RIL was 21% at 12 months, 42% at 36 months, and 48% at 60 months. Age > 60 years, smoking, and the germline SNP rs2120825 (PPARg locus) were associated with an increased risk of RIL. Our study identified potential risk factors for the development of RIL (age, smoking, and the germline SNP rs2120825) and established the rationale for testing PPARg agonists in the prevention and management of late-delayed radiation-induced neurotoxicity.
Identifiants
pubmed: 33986314
doi: 10.1038/s41598-021-89216-1
pii: 10.1038/s41598-021-89216-1
pmc: PMC8119685
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10176Références
J Cancer Res Clin Oncol. 2019 Feb;145(2):337-344
pubmed: 30417218
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):870-7
pubmed: 19801103
J Clin Oncol. 1998 Mar;16(3):864-71
pubmed: 9508167
Neurology. 2004 Feb 24;62(4):548-55
pubmed: 14981169
Radiat Res. 2014 Jan;181(1):33-44
pubmed: 24397438
Arch Neurol. 2005 Oct;62(10):1595-600
pubmed: 16216945
Lancet Oncol. 2016 Mar;17(3):e97-e108
pubmed: 26972863
Rev Neurol (Paris). 2011 Oct;167(10):737-45
pubmed: 21899866
Cochrane Database Syst Rev. 2019 Aug 05;8:CD013047
pubmed: 31425631
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Radiat Res. 2000 Apr;153(4):357-70
pubmed: 10798963
J Neurooncol. 2001 Mar;52(1):73-80
pubmed: 11451205
Lancet. 2017 Oct 7;390(10103):1645-1653
pubmed: 28801186
Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):52-7
pubmed: 12524224
Neurosurgery. 2001 Nov;49(5):1166-84; discussion 1184-6
pubmed: 11846911
Lancet. 2012 May 26;379(9830):1984-96
pubmed: 22510398
Neuro Oncol. 2021 May 5;23(5):803-811
pubmed: 33130890
Radiother Oncol. 2002 Aug;64(2):131-40
pubmed: 12242122
Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):762-8
pubmed: 12663374
Fundam Clin Pharmacol. 2015 Jun;29(3):286-98
pubmed: 25824615
Blood Press. 2006;15(2):71-9
pubmed: 16754269
Lancet Neurol. 2002 Nov;1(7):426-36
pubmed: 12849365
PLoS One. 2012;7(11):e50500
pubmed: 23185633
Arch Neurol. 1993 Aug;50(8):873-80
pubmed: 8352676
Clin Cancer Res. 2006 Dec 1;12(23):7063-70
pubmed: 17145829
J Neuropathol Exp Neurol. 2011 Oct;70(10):900-12
pubmed: 21937914
Neurology. 2004 Feb 10;62(3):451-6
pubmed: 14872029
J Neurooncol. 2014 Jan;116(2):387-94
pubmed: 24264531
Support Care Cancer. 2018 Dec;26(12):4217-4226
pubmed: 29982900
ASN Neuro. 2013 Dec 18;5(5):e00129
pubmed: 24215544
Int Immunopharmacol. 2017 Feb;43:53-61
pubmed: 27940378
J Neurol Sci. 1993 Jan;114(1):7-12
pubmed: 8433101
J Hypertens. 2012 Feb;30(2):315-26
pubmed: 22179086
Neurology. 2014 Jul 22;83(4):320-7
pubmed: 24944262
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):6-9
pubmed: 17189061
Radiother Oncol. 2003 Nov;69(2):127-35
pubmed: 14643949
J Neuropathol Exp Neurol. 2009 Jul;68(7):797-808
pubmed: 19535992
Oral Oncol. 2012 Nov;48(11):1090-100
pubmed: 22939215
Rev Neurol (Paris). 2011 Oct;167(10):746-50
pubmed: 21889778
Lung Cancer. 2015 Dec;90(3):405-9
pubmed: 26791799
Front Neurol. 2017 Jun 15;8:286
pubmed: 28663738
Radiat Oncol. 2013 May 22;8:125
pubmed: 23697595
Semin Radiat Oncol. 2010 Oct;20(4):232-40
pubmed: 20832015
Hum Mol Genet. 2011 Jul 15;20(14):2897-904
pubmed: 21531791
Front Neurosci. 2014 Jun 12;8:145
pubmed: 24971048
Neurology. 2004 Jul 27;63(2):246-53
pubmed: 15277616
Lancet. 2009 Nov 7;374(9701):1639-51
pubmed: 19897130